SRA Reliance Pathway for Medical Device Registration in Ethiopia

1. Key takeaways

Ethiopia operates a Stringent Regulatory Authority (SRA) reliance route: devices that already hold a marketing authorization, registration certificate or free sale certificate issued by any one of the 8 recognized regulatory authorities, or that carry World Health Organization (WHO) prequalification or United Nations Population Fund (UNFPA) prequalification, may enter Ethiopia through this channel. Its defining feature is that the number of dossier items is not reduced, but the review focuses on verifying authenticity, and processing time is shorter. For manufacturers seeking a predictable entry into Ethiopia, this is the fast lane with the highest degree of certainty.

The certainty comes from two sources. First, the eligibility test is objective: either the approving authority appears on the recognized list, or the product carries WHO or UNFPA prequalification, and neither condition depends on negotiation. Second, the evidence package is largely already in existence — the same certificates that supported approvals in other markets are the ones that support the Ethiopian reliance claim. The remaining risk sits in execution: citing an authority that is not on the current list, or labeling evidence incorrectly, converts the fast lane into a rejection.

2. Legal basis

3. Expert insights

Insight 1: the definition of an SRA emphasizes enforcement power, not institutional fame. Section 9.4 of the general guidelines defines an SRA as a stringent government authority or other entity that exercises full legal control over the use or sale of medical devices within its jurisdiction and can take enforcement actions to ensure that devices on the market fully comply with legal requirements. The test is whether the authority can actually enforce — not how well known the institution is. A regulator with genuine inspection, recall and sanction powers qualifies; a well-publicized body without those legal tools does not. Companies should therefore screen candidate approvals against the enforcement criterion before citing them.

Insight 2: the European Union entry is worded as the competent authorities of the 27 EU member states, not the EU as a whole. Item 5 of the list reads: the competent authorities of the 27 EU member states responsible for overseeing Directives 93/42/EEC and 98/79/EC and Regulations MDR 745/2017 and IVDR 746/2017. A company holding CE certificates must state which specific member state competent authority (or notified body system) oversees its approval. Writing the EU generically in the reliance justification leaves the eligibility claim half-argued and invites a query at screening that could have been avoided with one precise sentence.

Insight 3: prequalification evidence may be presented in three forms. Because WHO / UNFPA prequalified products may not hold a registration certificate or marketing authorization certificate, Section 9.4 allows the prequalification claim to be supported by any of the following: a confirmation letter that the product was accepted for prequalification; evidence that the product appears on the list of prequalified products; or an evaluation report on the device issued by the prequalification organization. This is especially critical for IVD manufacturers that hold only WHO PQ without a national registration certificate, since without one of these three documents the reliance claim has nothing to rest on.

Insight 4: the route is available, not automatically approved. The general guidelines state that the level of assurance provided by an SRA approval may not be the same when the device is used in Ethiopia, and that where the authority considers it necessary, it may conduct a complete evaluation and request supplementary information. Reliance accelerates the process; it does not outsource the regulatory decision. Companies must still prepare the technical dossier to Full Assessment standard, so that a conversion to in-depth review can be answered without rebuilding the file under deadline pressure.

Insight 5: the recognized list is updated, and the current publication prevails. Section 9.4 states that the list of authorities recognized by EFDA as SRAs will be updated where the authority considers it necessary. Arguing eligibility from an outdated list risks challenge at the screening stage. Before every submission — and again before any response to a query — the cited authority should be re-checked against the list as currently published, and the version consulted should be recorded in the project file.

4. Practical recommendations

1. Compare the current SRA list before deciding the pathway: do not rely on experience or memory.
2. CE certificate holders must state the specific member state competent authority: avoid writing the EU generically.
3. For WHO PQ products, prepare one of the three evidence forms: confirmation letter, list entry, or evaluation report.
4. Still prepare the technical dossier against the Full Assessment checklist: be ready for a possible conversion to in-depth review.
5. Never label non-SRA evidence as SRA: misleading submissions are rejected outright.
6. State the reliance basis proactively in the cover letter: it helps the screening stage classify the file quickly.

5. Verification checklist

• □ Approving authority confirmed to be on the current SRA list
• □ Marketing authorization, registration certificate or free sale certificate prepared
• □ WHO / UNFPA prequalification supported by a confirmation letter, list entry or evaluation report
• □ Technical dossier complete against the Full Assessment checklist
• □ Reliance basis stated in the application cover letter
• □ Confirmed that no non-SRA evidence has been mislabeled as SRA

Regulatory information verified as of October 29, 2026. The SRA list and the prequalification evidence forms described in this article follow the current text of Section 9.4 of EFDA-GDL-046; when the list is updated, the content must be re-verified.

• Ethiopia local resource: GRZAN supports manufacturers from the Chinese mainland and overseas in working with the Ethiopian Food and Drug Authority (EFDA) on marketing authorization (MA) applications, the institutional competency certificate (CoC) and import permit applications, including local agent scheme design and agency agreement review, SRA reliance route justification, UMDN coding and classification determination, technical dossier preparation, and vigilance and post-market surveillance system setup.
• Service capabilities: product attribute determination and risk classification (non-IVD Class I–IV / IVD Class A–D), marketing authorization applications and re-registration, low-risk notification eligibility determination, Essential Principles conformity justification, English-language labeling and instructions-for-use localization, vigilance reporting and field safety corrective action support.
• Contact: hito.lin@grzan.cn; website www.grzan.cn. For EFDA registration pathway and classification strategy support for the Ethiopian market, write to info@grzanglobal.com.